{"id":8012,"date":"2023-12-05T12:44:15","date_gmt":"2023-12-05T12:44:15","guid":{"rendered":"https:\/\/dailyai.com\/?p=8012"},"modified":"2023-12-05T12:48:06","modified_gmt":"2023-12-05T12:48:06","slug":"astrazeneca-bets-247m-on-ai-company-developing-cancer-drug","status":"publish","type":"post","link":"https:\/\/dailyai.com\/de\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/","title":{"rendered":"AstraZeneca investiert $247 Millionen in ein KI-Unternehmen, das ein Krebsmedikament entwickelt"},"content":{"rendered":"<p><strong>AstraZeneca hat $247 Millionen zugesagt, um die Bem\u00fchungen des KI-Wirkstoffforschungsunternehmens Absci zur Entwicklung eines Antik\u00f6rpers gegen Krebs zu finanzieren.<\/strong><\/p>\n<p>Absci nutzt seine generative <a href=\"https:\/\/dailyai.com\/de\/2023\/07\/ai-accelerates-discovery-of-anti-aging-drugs-in-new-study\/\">AI-Arzneimittelentdeckung<\/a> Plattform zur Entdeckung potenzieller neuer Arzneimittel und validiert diese anschlie\u00dfend in ihren Nasslabors.<\/p>\n<p>Mit dem von AstraZeneca unterst\u00fctzten Projekt wird Absci versuchen, einen Antik\u00f6rper zu entwickeln, der an ein spezifisches onkologisches Ziel bindet. Das Unternehmen hat noch nicht bekannt gegeben, auf welche Art von Krebs es mit diesem Projekt abzielt.<\/p>\n<p>Antik\u00f6rper sind eine attraktive Perspektive f\u00fcr <a href=\"https:\/\/dailyai.com\/de\/2023\/06\/researchers-build-breakthrough-ai-model-for-drug-discovery\/\">neue Medikamente<\/a> weil sie hochselektiv in Bezug auf die Ziele sind, an die sie binden, und nur minimale immunogene Wirkungen haben. Es ist jedoch schwierig, einen leicht herstellbaren neuen Antik\u00f6rper mit spezifischen Eigenschaften zu finden.<\/p>\n<p>Die Zahl der m\u00f6glichen Proteinkombinationen zur Herstellung verschiedener Antik\u00f6rper ist praktisch unbegrenzt. Um einen zu finden, der das tut, was man will, muss man also ein wenig raten und ausprobieren.<\/p>\n<p>Dies macht die herk\u00f6mmliche Antik\u00f6rperentdeckung sehr zeit- und ressourcenaufw\u00e4ndig. Sie umfasst das Screening gro\u00dfer Immun- oder synthetischer Bibliotheken, um potenzielle Antik\u00f6rperkandidaten zu finden. Diese Kandidaten m\u00fcssen dann synthetisiert werden, bevor best\u00e4tigt werden kann, ob sie optimal an das Ziel binden.<\/p>\n<p>Die Integrated Drug Creation Plattform von Absci verwendet maschinelle Lernmodelle, die auf Nasslabor-Assays oder experimentellen Verfahren trainiert sind und Milliarden von Protein-Protein-Interaktionsdaten erzeugen.<\/p>\n<p>Das KI-Modell erlernt die zugrundeliegenden technischen Prinzipien, die das Verhalten der verschiedenen Proteine bestimmen. Die Plattform setzt ihre generative KI-Engine ein, um synthetische Antik\u00f6rper de novo oder von Grund auf neu zu erstellen, und zwar in einem Zero-Shot-Ansatz.<\/p>\n<p>Bei Antik\u00f6rpern bedeutet ein Zero-Shot-Ansatz, dass die von der KI generierten Kandidatenproteine auf ersten Prinzipien beruhen und nicht auf historischen Daten anderer Proteine, von denen bekannt ist, dass sie an einen bestimmten Erreger binden.<\/p>\n<p>Der Einsatz von KI erm\u00f6glicht eine viel schnellere und pr\u00e4zisere \"Vermutung\", welche Proteine potenziell untersuchungsw\u00fcrdig sein k\u00f6nnten, als der menschliche \"Hit-and-Miss\"-Ansatz.<\/p>\n<p>Die in Frage kommenden Proteine werden dann in den Nasslabors von Absci experimentell validiert. Die KI-Plattform f\u00fcr das Proteindesign beschleunigt die Entdeckung von Medikamenten, indem sie den Zyklus von Datenerfassung, KI-gesteuertem Design und Validierung im Nasslabor innerhalb von etwa sechs Wochen abschlie\u00dft.<\/p>\n<p>Sean McClain, CEO von Absci, sagte \u00fcber die Partnerschaft mit AstraZeneca: \"AstraZeneca ist f\u00fchrend in der Entwicklung neuartiger Behandlungen in der Onkologie, und wir freuen uns, mit ihnen zusammenzuarbeiten, um einen therapeutischen Antik\u00f6rperkandidaten zu entwickeln, der das Potenzial hat, das Leben von Krebspatienten zu verbessern.<\/p>\n<p>Das finanzielle Engagement von AstraZeneca f\u00fcr das Projekt ist ein vielversprechendes Zeichen daf\u00fcr, dass das Unternehmen die Erfolgsaussichten optimistisch einsch\u00e4tzt. Einsatz von KI zur Beschleunigung der Entwicklung von <a href=\"https:\/\/dailyai.com\/de\/2023\/08\/ai-powered-blood-test-detects-cancers-in-single-dna-molecules\/\">Krebs<\/a> Medikamente werden einen gro\u00dfen Einfluss auf das Leben der Patienten und auf die Finanzen von Big Pharma haben.<\/p>","protected":false},"excerpt":{"rendered":"<p>AstraZeneca hat $247 Millionen zugesagt, um die Bem\u00fchungen des KI-Wirkstoffforschungsunternehmens Absci zur Entwicklung eines Antik\u00f6rpers gegen Krebs zu finanzieren. Absci nutzt seine generative KI-Plattform zur Arzneimittelentdeckung, um potenzielle neue Arzneimittel zu entdecken und diese dann in seinen Nasslabors zu validieren. Mit dem von AstraZeneca unterst\u00fctzten Projekt wird Absci versuchen, einen Antik\u00f6rper zu entwickeln, der an ein bestimmtes onkologisches Ziel bindet. Das Unternehmen hat noch nicht bekannt gegeben, auf welche Art von Krebs es mit diesem Projekt abzielt. Antik\u00f6rper sind ein attraktiver Kandidat f\u00fcr neue Medikamente, da sie sehr selektiv an die Ziele binden und nur minimale immunogene Wirkungen haben. Allerdings ist die Suche nach einem<\/p>","protected":false},"author":6,"featured_media":8014,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[84],"tags":[150,203,107],"class_list":["post-8012","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-industry","tag-ai-benefits","tag-biotech","tag-generative-ai"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AstraZeneca bets $247m on AI company developing cancer drug | DailyAI<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dailyai.com\/de\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca bets $247m on AI company developing cancer drug | DailyAI\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca has committed $247 million to fund AI drug discovery company Absci\u2019s efforts to develop an antibody for cancer. Absci uses its generative AI drug discovery platform to discover potential new drugs and then validates these in its wet-labs. With the AstraZeneca-backed project, Absci will try to create an antibody that binds to a specific oncology target. The company hasn\u2019t yet revealed which type of cancer it is targeting with this project. Antibodies are an attractive prospect for new drugs because they are highly selective in the targets they bind to and result in minimal immunogenic effects. However, finding an\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dailyai.com\/de\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/\" \/>\n<meta property=\"og:site_name\" content=\"DailyAI\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-05T12:44:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-12-05T12:48:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/12\/antibody-proteins.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"501\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Eugene van der Watt\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DailyAIOfficial\" \/>\n<meta name=\"twitter:site\" content=\"@DailyAIOfficial\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Eugene van der Watt\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/\"},\"author\":{\"name\":\"Eugene van der Watt\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/#\\\/schema\\\/person\\\/7ce525c6d0c79838b7cc7cde96993cfa\"},\"headline\":\"AstraZeneca bets $247m on AI company developing cancer drug\",\"datePublished\":\"2023-12-05T12:44:15+00:00\",\"dateModified\":\"2023-12-05T12:48:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/\"},\"wordCount\":434,\"publisher\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/antibody-proteins.jpg\",\"keywords\":[\"AI benefits\",\"Biotech\",\"Generative AI\"],\"articleSection\":[\"Industry\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/\",\"url\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/\",\"name\":\"AstraZeneca bets $247m on AI company developing cancer drug | DailyAI\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/antibody-proteins.jpg\",\"datePublished\":\"2023-12-05T12:44:15+00:00\",\"dateModified\":\"2023-12-05T12:48:06+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/#primaryimage\",\"url\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/antibody-proteins.jpg\",\"contentUrl\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/antibody-proteins.jpg\",\"width\":1000,\"height\":501},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/dailyai.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca bets $247m on AI company developing cancer drug\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/#website\",\"url\":\"https:\\\/\\\/dailyai.com\\\/\",\"name\":\"DailyAI\",\"description\":\"Your Daily Dose of AI News\",\"publisher\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/dailyai.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/#organization\",\"name\":\"DailyAI\",\"url\":\"https:\\\/\\\/dailyai.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/Daily-Ai_TL_colour.png\",\"contentUrl\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/Daily-Ai_TL_colour.png\",\"width\":4501,\"height\":934,\"caption\":\"DailyAI\"},\"image\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/DailyAIOfficial\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/dailyaiofficial\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@DailyAIOfficial\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/#\\\/schema\\\/person\\\/7ce525c6d0c79838b7cc7cde96993cfa\",\"name\":\"Eugene van der Watt\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/Eugine_Profile_Picture-96x96.png\",\"url\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/Eugine_Profile_Picture-96x96.png\",\"contentUrl\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/Eugine_Profile_Picture-96x96.png\",\"caption\":\"Eugene van der Watt\"},\"description\":\"Eugene comes from an electronic engineering background and loves all things tech. When he takes a break from consuming AI news you'll find him at the snooker table.\",\"sameAs\":[\"www.linkedin.com\\\/in\\\/eugene-van-der-watt-16828119\"],\"url\":\"https:\\\/\\\/dailyai.com\\\/de\\\/author\\\/eugene\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AstraZeneca wettet $247m auf AI-Unternehmen, das Krebsmedikament entwickelt | DailyAI","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dailyai.com\/de\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/","og_locale":"de_DE","og_type":"article","og_title":"AstraZeneca bets $247m on AI company developing cancer drug | DailyAI","og_description":"AstraZeneca has committed $247 million to fund AI drug discovery company Absci\u2019s efforts to develop an antibody for cancer. Absci uses its generative AI drug discovery platform to discover potential new drugs and then validates these in its wet-labs. With the AstraZeneca-backed project, Absci will try to create an antibody that binds to a specific oncology target. The company hasn\u2019t yet revealed which type of cancer it is targeting with this project. Antibodies are an attractive prospect for new drugs because they are highly selective in the targets they bind to and result in minimal immunogenic effects. However, finding an","og_url":"https:\/\/dailyai.com\/de\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/","og_site_name":"DailyAI","article_published_time":"2023-12-05T12:44:15+00:00","article_modified_time":"2023-12-05T12:48:06+00:00","og_image":[{"width":1000,"height":501,"url":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/12\/antibody-proteins.jpg","type":"image\/jpeg"}],"author":"Eugene van der Watt","twitter_card":"summary_large_image","twitter_creator":"@DailyAIOfficial","twitter_site":"@DailyAIOfficial","twitter_misc":{"Verfasst von":"Eugene van der Watt","Gesch\u00e4tzte Lesezeit":"2\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/#article","isPartOf":{"@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/"},"author":{"name":"Eugene van der Watt","@id":"https:\/\/dailyai.com\/#\/schema\/person\/7ce525c6d0c79838b7cc7cde96993cfa"},"headline":"AstraZeneca bets $247m on AI company developing cancer drug","datePublished":"2023-12-05T12:44:15+00:00","dateModified":"2023-12-05T12:48:06+00:00","mainEntityOfPage":{"@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/"},"wordCount":434,"publisher":{"@id":"https:\/\/dailyai.com\/#organization"},"image":{"@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/#primaryimage"},"thumbnailUrl":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/12\/antibody-proteins.jpg","keywords":["AI benefits","Biotech","Generative AI"],"articleSection":["Industry"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/","url":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/","name":"AstraZeneca wettet $247m auf AI-Unternehmen, das Krebsmedikament entwickelt | DailyAI","isPartOf":{"@id":"https:\/\/dailyai.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/#primaryimage"},"image":{"@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/#primaryimage"},"thumbnailUrl":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/12\/antibody-proteins.jpg","datePublished":"2023-12-05T12:44:15+00:00","dateModified":"2023-12-05T12:48:06+00:00","breadcrumb":{"@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/#primaryimage","url":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/12\/antibody-proteins.jpg","contentUrl":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/12\/antibody-proteins.jpg","width":1000,"height":501},{"@type":"BreadcrumbList","@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/dailyai.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca bets $247m on AI company developing cancer drug"}]},{"@type":"WebSite","@id":"https:\/\/dailyai.com\/#website","url":"https:\/\/dailyai.com\/","name":"DailyAI","description":"Ihre t\u00e4gliche Dosis an AI-Nachrichten","publisher":{"@id":"https:\/\/dailyai.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dailyai.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/dailyai.com\/#organization","name":"DailyAI","url":"https:\/\/dailyai.com\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/dailyai.com\/#\/schema\/logo\/image\/","url":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/06\/Daily-Ai_TL_colour.png","contentUrl":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/06\/Daily-Ai_TL_colour.png","width":4501,"height":934,"caption":"DailyAI"},"image":{"@id":"https:\/\/dailyai.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/DailyAIOfficial","https:\/\/www.linkedin.com\/company\/dailyaiofficial\/","https:\/\/www.youtube.com\/@DailyAIOfficial"]},{"@type":"Person","@id":"https:\/\/dailyai.com\/#\/schema\/person\/7ce525c6d0c79838b7cc7cde96993cfa","name":"Eugene van der Watt","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/07\/Eugine_Profile_Picture-96x96.png","url":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/07\/Eugine_Profile_Picture-96x96.png","contentUrl":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/07\/Eugine_Profile_Picture-96x96.png","caption":"Eugene van der Watt"},"description":"Eugene kommt aus der Elektronikbranche und liebt alles, was mit Technik zu tun hat. Wenn er eine Pause vom Konsum von KI-Nachrichten einlegt, findet man ihn am Snookertisch.","sameAs":["www.linkedin.com\/in\/eugene-van-der-watt-16828119"],"url":"https:\/\/dailyai.com\/de\/author\/eugene\/"}]}},"_links":{"self":[{"href":"https:\/\/dailyai.com\/de\/wp-json\/wp\/v2\/posts\/8012","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dailyai.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dailyai.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dailyai.com\/de\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/dailyai.com\/de\/wp-json\/wp\/v2\/comments?post=8012"}],"version-history":[{"count":5,"href":"https:\/\/dailyai.com\/de\/wp-json\/wp\/v2\/posts\/8012\/revisions"}],"predecessor-version":[{"id":8018,"href":"https:\/\/dailyai.com\/de\/wp-json\/wp\/v2\/posts\/8012\/revisions\/8018"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dailyai.com\/de\/wp-json\/wp\/v2\/media\/8014"}],"wp:attachment":[{"href":"https:\/\/dailyai.com\/de\/wp-json\/wp\/v2\/media?parent=8012"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dailyai.com\/de\/wp-json\/wp\/v2\/categories?post=8012"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dailyai.com\/de\/wp-json\/wp\/v2\/tags?post=8012"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}